U.S. markets close in 4 hours 48 minutes

Bionano Genomics, Inc. (BNGO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5010-0.0066 (-1.30%)
As of 11:12AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.5076
Open0.5070
Bid0.4965 x 1000
Ask0.4970 x 1100
Day's Range0.4965 - 0.5070
52 Week Range0.2500 - 1.5000
Volume1,018,743
Avg. Volume9,141,373
Market Cap72.469M
Beta (5Y Monthly)1.54
PE Ratio (TTM)N/A
EPS (TTM)-0.7960
Earnings DateNov 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.48
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Prowess of Bionano Genomics’ Saphyr System in Uncovering Novel Genetic Variations That Cause Cancer and Genetic Disease in Full Display at ASHG 2020
    GlobeNewswire

    Prowess of Bionano Genomics’ Saphyr System in Uncovering Novel Genetic Variations That Cause Cancer and Genetic Disease in Full Display at ASHG 2020

    Top researchers present discoveries in cancer predisposition, neurodegenerative diseases, microdeletion syndromes and other genetic disorders made using Bionano’s optical genome mapping technologySAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that human genetics researchers using the Saphyr system will present their results at the American Society of Human Genetics (ASHG) Annual Meeting, being held virtually at www.ashg.org between October 27-30. The impact of structural variation analysis using the Saphyr system will be demonstrated at ASHG with 18 oral and poster presentations which cover an expanding array of diseases like cancer predisposition, microdeletion syndromes, repeat expansion disorders, neurodegenerative diseases, disorders of sex development and a variety of other genetic diseases. Additionally, these presentations show Saphyr’s abilities to elucidate the exact structure of complex genomic rearrangements such as large inversions, chromothripsis and low copy repeats. “The scientific importance and quality of the studies utilizing Saphyr and presented at ASHG have increased year over year,” said Erik Holmlin, Ph.D., CEO of Bionano. “As more scientists present and publish their important discoveries made with Saphyr, an increasing number of potential future Saphyr users become aware of its prowess in uncovering novel genetic variants that contribute to cancer and genetic disease, which could drive more adoption and utilization for basic genetic research and clinical studies alike.”Below is a summary of key presentations to be given at ASHG 2020 featuring the use of Bionano’s optical genome mapping technology:Live Presentation – October 29, 2020, 11:45AM-12:00PM Deciphering Genomic Inversions Christopher M. Grochowski, Baylor College of Medicine Genomic inversions are a class of structural variation (SV) relevant in evolution, speciation, and human disease but challenging to detect and resolve using current genomic assays. While short-read WGS can detect a fraction of copy number neutral inversions, those mediated by repeats or accompanied by CNVs remain challenging. The utilization of multiple technologies and visualization of unbroken DNA through long molecule approaches facilitate detection of in cis events and resolution of SVs containing two or more breakpoint junctions.The following Co-Labs, Poster Sessions and Abstracts are available for on-demand viewing during and after ASHG 2020:Bionano Laboratory Co-Lab Session: Resolving Complex Haplotypes Implicated in Alzheimer’s and Other Neurodegenerative Diseases. Mark T. W. Ebbert, Neuroscience Department, Mayo Clinic Alzheimer’s disease is genetically complex with no meaningful therapies or pre-symptomatic disease diagnostics. Most of the genes implicated in Alzheimer’s disease do not have a known functional mutation, meaning there are no known molecular mechanisms to help understand disease etiology. In this co-lab session, Mark T. W. Ebbert of the Mayo Clinic will discuss his team’s work toward identifying functional structural mutations that drive disease in order to facilitate a meaningful therapy and pre-symptomatic disease diagnostic. Some of the genes and regions implicated in Alzheimer’s disease are genomically complex and cannot be resolved with short-read sequencing technologies. These regions include MAPT, CR1, and the histocompatibility complex (including the HLA genes). 3342 – Bionano Poster Session: High Throughput Analysis of Disease Repeat Expansions and Contractions by Optical Mapping Ernest Lam, Sr Manager Bioinformatics, Bionano Genomics Repeat expansions and contractions are associated with degenerative disorders such as facioscapulohumeral muscular dystrophy (FSHD). Southern Blotting is the gold standard for long repeat analysis but has many limitations. Optical genome mapping allows for efficient analysis of diseases associated with repeat expansion and contraction.2190 – Bionano Poster Session: Rapid Automated large Structural Variation Detection in Mouse Genome by Whole Genome Sequencing Jill Lai, Sr Applications Scientist, Bionano Genomics Identifying SVs for key model organisms such as mouse and rat is essential for genome interpretation and disease studies but has been historically difficult due to limitations inherent to available genome technologies. We updated the Saphyr analysis pipeline such that copy number variant (CNV) and SV analyses could now be applied to mouse and other non-human species, and constructed a control SV database for annotating variants, and identified strain-specific SVs/CNVs as well as variation shared among strains.Additional presentations/abstracts featuring optical genome mapping:3208 - Long-read sequencing and optical mapping decipher structural composition of ATXN10 repeat in kindred with spinocerebellar ataxia and Parkinson’s disease Presented by Birgitt Schuele, Associate Professor, Department of Pathology, Stanford University School of Medicine3270 - Uniparental isodisomy, structural and noncoding variants involved in inherited retinal degeneration (IRD) in three pedigrees Presented by Pooja Biswas, Ophthalmology Department, University of California, San DiegoData CoLab: Whole Genome Map Assembly and Structural Variation Analysis with Hitachi Human Chromosome Explorer™ Presented by Hitachi-High-Tech America, Inc.2123 - High-throughput sequencing and mapping technologies applied to 10 human genomes with chromothripsis-like rearrangements Presented by Uirá Souto Melo, Mundlos Lab, Max Planck Institute for Molecular Genetics, Berlin, Germany2165 - nanotatoR: A tool for enhanced annotation of genomic structural variants Presented by Emmanuele Delot, Center for Genetic Medicine Research, Children’s National Hospital, Washington, DC2998 \- Highly variable structure and organization of the human 3q29 subtelomeric segmental duplications Presented by Umamaheswaran Gurusamy, Cardiovascular Research Institute, University of California San Francisco2304 - Enlightening the dark matter of the genome: Whole genome imaging identifies a germline retrotransposon insertion in SMARCB1in two siblings with atypical teratoid rhabdoid tumor Presented by Mariangela Sabatella, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands2318 \- FaNDOM: Fast Nested Distance-based seeding of Optical Maps Presented by Siavash Raeisi Dehkordi, Computer Science & Engineering, University of California San Diego, La Jolla3023 \- Structural hypervariability of low copy repeats on chromosome 22 is human specific Presented by Lisanne Vervoort, Department of Human Genetics, KU Leuven, Leuven, Belgium3024 \- Telomere-to-telomere assembly and complete comparative sequence analysis of the human chromosome 8 centromere Reviewer's Choice Award Recipient Presented by Glennis Logsdon, Genome Sciences, University of Washington, Seattle, WA3311 \- Comprehensive structural variant identification with optical genome mapping and short-read sequencing for diagnosis of disorders/differences of sex development (DSD) Reviewer's Choice Award Recipient Presented by Hayk Barseghyan, Center for Genetic Medicine Research, Children's National Hospital, Washington, DC3318 \- De novo mutation and skewed X-inactivation in girl with BCAP31-related syndrome Presented by H.J. Kao, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan3560 \- Resolving genomic structures in MECP2 Duplication Syndrome provides insight into genotype-phenotype correlations Reviewer's Choice Award Recipient Presented by Davut Pehlivan, Molecular and Human Genetics, Baylor College of Medicine, Houston, TX2157 - methometR: quantification of long-range haplotype specific methylation levels from Optical Genome Maps Presented by Surajit Bhattacharya, Center for Genetic Medicine Research, Children’s Research Institute, Children’s National Hospital, Washington, DCAbout Bionano Genomics Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano’s Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. For more information, visit www.bionanogenomics.com or www.lineagen.com.Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the timing and content of the presentations identified in this press release; the effectiveness and utility of Bionano’s technology in basic genetic research and clinical settings; the contribution of Saphyr to uncovering novel genetic variants that contribute to cancer and genetic disease; the benefits of Bionano’s optical mapping technology and its ability to facilitate genomic analysis in future studies; and Bionano’s strategic plans. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise. CONTACTS Company Contact: Erik Holmlin, CEO Bionano Genomics, Inc. +1 (858) 888-7610 eholmlin@bionanogenomics.comInvestor Relations Contact: Ashley R. Robinson LifeSci Advisors, LLC +1 (617) 430-7577 arr@lifesciadvisors.comMedia Contact: Darren Opland, PhD LifeSci Communications +1 (617) 733-7668 darren@lifescicomms.com

  • Rockefeller University Scientist Uses Bionano Saphyr to Analyze Genomes of Patients and Animals Susceptible to COVID-19
    GlobeNewswire

    Rockefeller University Scientist Uses Bionano Saphyr to Analyze Genomes of Patients and Animals Susceptible to COVID-19

    Using Bionano data in comparative genomics analysis of patients with severe disease and animals that are susceptible to SARS-CoV-2 against patients and animals resistant to disease may reveal biomarkers for COVID-19 risk and how to treat itSAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that Dr. Erich Jarvis, a Howard Hughes Medical Institute investigator at the Rockefeller University and Chair of the Vertebrate Genome Project (VGP), is bringing his expertise in comparative genomics to the COVID-19 Host Genome SV Consortium as a co-principal investigator. The consortium, founded by Dr. Ravindra Kolhe at Augusta University, is centered around the analysis with Saphyr of structural variants (SVs) in the human genome that predispose to or protect against COVID-19. Identifying such variants in the genome can lead to the development of novel drugs, the repurposing of existing drugs for COVID-19, the development of targeted vaccines and importantly, the identification of risk markers that allow better triaging of patients who need certain treatment or early access to vaccines. Dr. Jarvis brings to the consortium a unique and powerful approach to understanding host response genetics called comparative genomics, in which genomes of different species with and without certain traits are compared to reveal the variants responsible for the traits of interest. In the case of COVID-19 response, the genomes of animals that are believed to be sensitive to SARS-CoV-2 infection will be compared to genomes of species presumed to be immune to infection or disease. The non-human animal species that were susceptible to SARS-CoV-2 infection to be included in the study are the Chinese horseshoe bat, a natural reservoir for the virus; the Chinese pangolin, an alternative reservoir; the clouded leopard, an animal that tested positive for SARS-CoV-2 infection in the Bronx Zoo; and four domestic species that are believed to be vulnerable: the sheep, Arabian camel, horse and Chinese hamster. For the human arm of the study, the Jarvis team will analyze the genomes of ten patients who were hospitalized and/or died from COVID-19. The genomes of ten individuals who did not get sick after exposure will function as controls along with those of more than one hundred vertebrate species assembled by the VGP and presumed to be resistant to infection.Analysis by comparative genomics requires complete genome assemblies for the species to be analyzed, and those assemblies have to be as accurate and complete as possible. The genome assembly team of the VGP has developed and optimized a pipeline utilizing long-read sequencing, Bionano optical maps, and a method called Hi-C to build reference-quality genomes. Data generated with Bionano’s Saphyr system are essential for these assemblies because Bionano data provide a level of structural accuracy required to achieve complete and accurate assemblies, as was demonstrated in a previously announced publication that showed Saphyr’s contribution to the first ever telomere-to-telomere assembly of a complete human X chromosome.Typical genome analysis studies use short-read sequencing technologies and have limits because they miss rare variants, cannot analyze parts of the genome that are absent from the reference and they suffer from incorrect alignments to structural variants and incomplete assemblies with gaps in important regions, such as complex, repetitive immune genes. Long-read sequencing data combined with structural variation data generated by Saphyr can build the high-quality genomes needed for the VGP, and provide the genome structural variation data needed to investigate the COVID-19 response across species. The comparative genomics approach to studying the various animal species and human patient genomes allows for a detailed characterization of conserved genetic elements, and may identify elements crucial to vulnerability or protection from infection. Dr. Jarvis and the VGP intend to include further focus on the ACE2 gene, which enables the virus to infect the cell, the MHC region that plays a crucial part in the immune response to the virus and analyze the rest of the genome as well. Many immune gene regions have been incompletely assembled in most draft genomes, making it impossible to do this type of comparative genomics analysis until complete reference quality genomes are available for each species. The high-quality genomes are the only available method to analyze point-mutations and structural variations together.Erik Holmlin, PhD, CEO of Bionano Genomics added: “The SARS-CoV-2 pandemic has turned the world on its side this year, leading to a concerted global effort by researchers to better understand how to properly combat this pandemic and who is most at risk of developing severe COVID-19. We believe the most effective way to develop and steer effective treatment is to better understand the genomic basis for COVID-19 susceptibility. This belief in part prompted the creation of the COVID-19 Host Genome SV Consortium, which brought scientists and clinicians together, using Saphyr as the core technology to find the structural variants that predispose to or protect against disease. We recently announced a publication by the VGP that deemed Bionano’s optical mapping technology an essential component to building complete reference-quality genomes, and we are excited to once again be a part of this innovative and globally important research effort, which could lead to better treatment and better selection of patients who need certain treatment or vaccines the most.”About Bionano Genomics Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano’s Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. For more information, visit www.bionanogenomics.com or www.lineagen.com.Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the expected scope of the consortium’s research, including the anticipated contribution of Dr. Jarvis and his team; the contribution of Bionano’s technology to the development or repurposing of drugs, improved treatment methods or vaccines for COVID-19 and the identification of related risk markers; Bionano’s expected contribution to the generation of high-quality, complete reference genomes; Saphyr’s capabilities in comparison to other genome analysis technologies; and the advancement of strategic objectives by the consortium, the VGP or Bionano. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise. CONTACTS Company Contact: Erik Holmlin, CEO Bionano Genomics, Inc. +1 (858) 888-7610 eholmlin@bionanogenomics.comInvestor Relations Contact: Ashley R. Robinson LifeSci Advisors, LLC +1 (617) 430-7577 arr@lifesciadvisors.comMedia Contact: Darren Opland, PhD +1 (617) 733-7668 darren@lifescicomms.com

  • New Strong Sell Stocks for October 22nd
    Zacks

    New Strong Sell Stocks for October 22nd

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today